Tyrosine Kinases as New Molecular Targets in Treatment of Inflammatory Disorders and Leukemia

Author(s): Fatih M. Uckun, Chen Mao

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 10 , 2004

Become EABM
Become Reviewer


Many protein tyrosine kinases (PTK), including Janus kinase 3 (JAK3) and Bruton ’ s tyrosine kinase (BTK), have been recently identified as potential drug targets to treat diverse diseases including inflammation and cancer. The wealth of structural information currently available for protein kinase-inhibitor complexes facilitates the structure-based design of novel kinase inhibitors. In this report, we discuss the structural basis of protein kinase inhibitor design and the common binding features of small molecule kinase inhibitors including pyridinyl imidazoles, purines, oxindoles, anilinoquinazolines and isoquinalines. The structural features of targeted kinase proteins and their inhibitor complexes are discussed with respect to their structure-and-activity relationships (SAR). We present a structural comparison of kinase inhibitors with a special emphasis on inhibitors of JAK3 and BTK.

Keywords: structure-based drug design, ptk, sar, btk, jak3, computational chemistry, inflammation, leukemia

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [1083 - 1091]
Pages: 9
DOI: 10.2174/1381612043452677
Price: $65

Article Metrics

PDF: 7